Explore the Agenda

Built with R&D, Clinical and Medical leaders at the forefront of innovation.

As investors and collaborators increasingly look for compelling in vivo strategies, explore the science and innovations reshaping cell therapy. Across autoimmune disease, oncology, and allergy, evaluate emerging approaches, eRNA and armored CAR and TCR designs and delivery strategies to benchmark your assets, accelerate development and enhance in vivo safety and persistence to make this emerging therapy a clinical and commercial reality.

Gain insight from:

8:00 am Check-In & Coffee

Welcome to the 11th CAR-TCR Summit. Settle in with refreshments as you spark early conversations with peers focused on the same priorities as you.

In Vivo Bootcamp

Discover the science, breakthroughs, and challenges driving momentum in in vivo therapies and what’s next for this rapidly evolving field. Whether you are actively developing in vivo therapies or exploring the space for the first time, this session is designed to build the insight needed to navigate one of the fastest-growing areas in cell and gene therapy.

Advancing In Vivo CAR Therapy Design & Strategy to Enable Next-Generation Clinical Success

9:00 am Disrupting the Autoimmune Disease Treatment Paradigm – Transient, Potent, & Scalable eRNA-based In Vivo CD19 CAR-T Therapy

Vice President, Immunology, Sail Biomedicines
  • Leveraging circular eRNA therapeutics and t-LNPs to drive potent, transient in vivo CAR-T cell engineering
  • Revolutionizing the autoimmune treatment paradigm by achieving deep B-cell depletion and “immune reboot” with a non-integrative product
  • Replacing ex vivo manufacturing with scalable, off-the-shelf IV-dosed therapy, eliminating the need for lymphoablation

9:30 am Panel Discussion: Investigating the Evolution of In Vivo Therapies to Accelerate Innovations

Vice President, Preclinical Sciences, Bristol Myers Squibb
Executive VP, Vyriad
Founder & Chief Executive Officer, AllerGene AI
  • Discussing the rapid progression of in vivo therapies, considering the impact on COGs and patient outcomes
  • Highlighting in vivo innovations to develop more effective, scalable, and accessible therapies
  • Evaluating what’s next for in vivo therapies to understand anticipated clinical progress, expanding disease indications and projected advancements for strategic planning

10:30 am Morning Break & Networking

Take a moment to pause with tea, coffee and refreshments, continue initial conversations and exchange fresh perspectives ahead of returning to the bootcamp session.

11:30 am Designing In Vivo T-Cell Therapies to Combat Resistance & Enhance Durability in Solid Tumors

Chief Scientific Officer, T-knife GmbH
  • Identifying mechanisms of resistance to understand impact in vivo CAR-T durability
  • Balancing armored CAR/TCR designs to optimize long-term efficacy while minimizing safety risks
  • Evaluating in vivo therapeutic approaches for treating solid tumors in complex tumor microenvironments

12:00 pm Expanding CAR-T Therapies Beyond Cancer & Autoimmune Diseases into Mast Cell Diseases, Allergy & Immunology

Founder & Chief Executive Officer, AllerGene AI
  • Exploring the underlying pathology of allergic diseases
  • Designing CAR-T therapies to eliminate mast cells, the cellular cause of allergic reactions
  • Defining the unmet need for mast cell targeting CAR-T cells

12:30 pm Lunch Break & Networking

Recharge over lunch while reflecting on the morning’s insights and uncovering new perspectives with your peers before heading into the afternoon session.

Evaluating Vector Delivery Approaches to Support Durable Activity & Sustainable In Vivo Development

1:30 pm Non-Viral ssDNA Vector Delivery Strategies to Optimize Persistence & Patient Safety

Head of RnD, CPTx
  • In vivo immune cell engineering with ssDNA
  • Developing strategies to allow long term persistence and gene expression
  • Preclinical evidence and scale up

2:00 pm Developing High-Quality Lentiviral Vectors to Enhance Reliable Delivery & Reduce Cost

Executive VP, Vyriad
  • Examining lentiviral delivery platforms to understand current industry benchmarks and opportunities for innovation
  • Optimizing vector design and production strategies to enhance durable CAR expression
  • Evaluating scalability and manufacturing readiness of lentiviral vectors to support sustainable in vivo clinical and commercial deployment

Defining Safety Assessment & Purity Standards to Support Regulatory-Ready In Vivo Therapies

2:30 pm Optimizing In Vivo LNP Delivery of CAR mRNAs to Unlock Autoimmune Disease Treatments

CSO, Aera Therapeutics, Inc
  • Optimizing LNP delivery systems for in vivo CAR-T 
  • Screening and selection of mRNA cargo 
  • Assembly of preclinical data package to support first in human studies

3:00 pm End of Bootcamp Day

3:30 pm C-Level Think Tank

Chief Business Development Officer, PolTREG

Scale Readiness Across Modalities

This invitation-only think tank designed exclusively for C-suite executives offers a rare opportunity to connect with cell therapy leaders across modalities and indications. Exchange perspectives, engage in depth discussions on the most pressing challenges, influence the direction of the field and gain strategic insights that extend beyond the summit.